. 2019 Dec 17;122(4):564–568. doi: 10.1038/s41416-019-0687-z

Table 4.

PPV and NPV according to the prevalence of SCCOHT in the target population.

	Tertiary Cancer Center (GRCC cohort)	Community setting (Projected)
Prevalence of SCCOHT	32%	5% (Estimated)
PPV	86.7% (73.8%–93.7%)^a	40% (21%–62%)^a
NPV	94.6% (88.0%–97.7%)^a	99% (93%–100%)^a

Tertiary Cancer Center
(GRCC cohort)

Community setting
(Projected)

Prevalence of SCCOHT

32%

(Estimated)

PPV

86.7%

(73.8%–93.7%)^a

40%

(21%–62%)^a

NPV

94.6%

(88.0%–97.7%)^a

99%

(93%–100%)^a

^aStandard logit Mercaldo 95% CI